Macro
Chiesi champions new inhaler propellant to reduce carbon footprint
UK-based Chiesi has invested in reducing its carbon footprint, with the development of a new inhaler propellant and the purchase…
Johnson & Johnson reports net earnings of $5.3bn in Q1 2024
Johnson & Johnson has reported a notable increase in its financial performance for the first quarter (Q1) of 2024, with…
Q&A: BARDA wants to back tech that can combat multiple infections, says director
Following the rapid development and commercialisation of Covid-19 vaccines and therapeutics, multiple pharmaceutical companies such as AstraZeneca, Moderna, and Pfizer…
Merck reports drop in net income for fiscal 2023
Merck KGaA (Merck) has reported a decline in financial performance for the fiscal year 2023, with net income attributable to…
Moderna reports net loss of $4.7bn for full year 2023
Moderna has reported a net loss of $4.7bn for the full year 2023 as against a net income of $8.4bn…
Everest ends Covid-19 mRNA vaccine deal with Providence
China-based Everest Medicine has terminated its licensing and partnership agreement with Canada-based Providence Therapeutics. Everest will pay $4m as part…
Psychedelic treatments for mental health: Is there substance behind the hype?
Psychedelic treatments have been considered in the treatment of mental health since the 1950s, following Albert Hofmann’s development of lysergic…
Q4 2023 update: environmental sustainability related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that environmental sustainability accounted for 6 pharmaceutical deals announced in Q4…
MHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for a variation in licence for Pfizer-BioNTech’s 30…
AstraZeneca posts 81% rise in FY 2023 profit after tax
AstraZeneca has reported a significant 81% rise in profit after tax, reaching $5.96bn for the fiscal year (FY) 2023 from…
